SheMed

Overview

SheMed is a UK-based health-tech company focused on personalizing healthcare solutions specifically for women. Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has become one of the fastest-growing startups in the women's healthcare industry. The company is known for its GLP-1 weight management program which aims to address unique female-specific health needs. As of 2025, SheMed has successfully secured $50 million in funding, achieving unicorn status with a valuation of $1 billion.

Recent Developments

October 2025: SheMed raised $50 million in a Series A funding round, elevating its valuation to $1 billion. This new infusion of capital will allow the company to expand its operations further within the UK and invest in strengthening its clinical infrastructure. The funding aims to support innovative healthcare solutions focusing on women's unique health requirements, especially in weight management using GLP-1 medications.
August 2025: In collaboration with Tasso, SheMed launched an at-home blood testing service as part of its treatment plan. This service ensures that patients receive personalized treatment plans based on thorough health screenings conducted through Tasso's blood-testing technology.
January 2025: The company reached unicorn status, reflecting investor confidence in its approach to addressing gaps in traditional women's healthcare by integrating personalized care with scientific and technological advances.
April 2024 to October 2025: Within its inaugural year, SheMed attracted over 60,000 members to its program. The company announced plans to publish a study assessing the impact of GLP-1 medicines on women's hormonal and metabolic health.

Attribute	Information
Founding Date	April 2024
Headquarters	London, United Kingdom
Founders	Olivia Ferro, Chloe Ferro
Revenue	Not publicly disclosed
Profits	Not publicly disclosed
Key Investors	Not publicly disclosed
Industry	Healthcare, HealthTech
Number of Employees	Approximately 60,000 members enrolled

Early History

SheMed was founded in April 2024 by Olivia and Chloe Ferro, driven by personal experiences of inadequacies in traditional healthcare settings for women. Their vision was to create a platform that not only addressed women’s health concerns with personalized and compassionate care but also incorporated cutting-edge technology. The focus was on providing scientifically-backed, personalized healthcare solutions, specifically targeting metabolic health issues like weight management through their GLP-1 platform.

Company Profile and Achievements

SheMed’s business model is centered around providing a personalized healthcare approach using digital and clinical tools tailored specifically for women's needs. The company uses GLP-1 receptor agonist medications to aid in weight management, offering a personalized treatment program that also includes comprehensive health screenings and continuous support through digital platforms, such as their proprietary app.

Milestones:
1. Secured $50 million in Series A funding within 18 months of inception, achieving unicorn status.
2. Developed partnerships for home diagnostics, enhancing personalized care.
3. Conducted clinical studies focused on women’s metabolic health.
4. Garnered a high adoption rate with over 60,000 women enrolled in under a year.

Current Operations and Market Position

SheMed finds itself as a leader in the health technology sector with a focus on women’s personalized care. It emphasizes replacing traditional one-size-fits-all healthcare models with solutions grounded in clinical precision. In the competitive UK health market, especially concerning weight management, SheMed’s reliance on GLP-1 treatments and comprehensive individualized health programs sets it apart from competitors primarily focused on standardized care.

Conclusion

SheMed is carving a significant niche in the health technology industry, specifically targeting women's healthcare by offering personalized, science-backed treatment plans. As it continues to innovate and expand, the company has potential implications beyond the borders of the UK by setting an example of how personalized medicine can address traditional healthcare gaps. With its foundation of compassionate and tailored care, SheMed demonstrates a keen trajectory toward broadening the scope and reach of its mission.